Tasosartan: Difference between revisions
No edit summary |
No edit summary |
||
| Line 24: | Line 24: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{ | {{SI}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
| Line 36: | Line 35: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{Agents acting on the renin-angiotensin system}} | {{Agents acting on the renin-angiotensin system}} | ||
[[Category:Angiotensin II receptor antagonists]] | [[Category:Angiotensin II receptor antagonists]] | ||
[[Category:Cardiovascular Drugs]][[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
Latest revision as of 21:09, 23 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C23H21N7O |
| Molar mass | 411.459 g/mol |
|
WikiDoc Resources for Tasosartan |
|
Articles |
|---|
|
Most recent articles on Tasosartan |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tasosartan at Clinical Trials.gov Clinical Trials on Tasosartan at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tasosartan
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tasosartan Discussion groups on Tasosartan Patient Handouts on Tasosartan Directions to Hospitals Treating Tasosartan Risk calculators and risk factors for Tasosartan
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tasosartan |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
- ↑ Atkinson AJ; et al. (2007). Principles of clinical pharmacology. Amsterdam: Elsevier. p. 515. ISBN 0-12-369417-5.
- ↑ Dina R, Jafari M (July 2000). "Angiotensin II-receptor antagonists: an overview". Am J Health Syst Pharm. 57 (13): 1231–41. PMID 10902066.
- Pages with script errors
- CS1 maint: Explicit use of et al.
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Angiotensin II receptor antagonists
- Cardiovascular Drugs
- Drug